Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Adjunctive Daptomycin in the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Randomized Controlled Trial

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Bloodstream infections (BSI) with methicillin-susceptible Staphylococcus aureus (MSSA) are associated with significant morbidity and mortality. The objective of our study was to determine the efficacy of synergistic treatment of daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI.

          Methods

          A randomized, double blind, placebo-controlled trial was performed at two academic hospitals in Montreal, Canada. Patients ≥ 18 years of age with MSSA BSI receiving either cefazolin or cloxacillin monotherapy were considered for inclusion. In addition to the standard of care treatment, participants received a 5-day course of adjunctive daptomycin or placebo. The primary outcome was the duration of MSSA BSI in days.

          Results

          Of 318 participants screened, 115 were enrolled and 104 were included in the intention to treat analysis (median age 67 years; 34.5% female). The median duration of bacteremia was 2.04 days among patients who received daptomycin versus 1.65 days in those who received placebo (absolute difference 0.39 days, p=0.40). A modified intention to treat analysis involving participants who remained bacteremic at the time of enrollment found a median duration of bacteremia of 3.06 days among patients who received daptomycin versus 3.0 days in those who received placebo (absolute difference 0.06 days, p=0.77). Ninety-day mortality in the daptomycin arm was 18.9% vs. 17.7% in the placebo arm (p=1.0).

          Conclusion

          Among patients with MSSA bloodstream infections, the administration of adjunctive daptomycin therapy to standard of care treatment did not shorten the duration of bacteremia and should not be routinely considered.

          Related collections

          Author and article information

          Journal
          Clinical Infectious Diseases
          Oxford University Press (OUP)
          1058-4838
          1537-6591
          July 15 2020
          July 15 2020
          Affiliations
          [1 ]Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
          [2 ]Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Canada
          [3 ]Division of Neonatology, Montreal Children’s Hospital, McGill University, Montreal, Canada
          [4 ]Research Institute of the McGill University Health Centre, Montreal, Canada
          [5 ]Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Canada
          Article
          10.1093/cid/ciaa1000
          © 2020

          https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

          Comments

          Comment on this article